3.81
+0.1(+2.70%)
Currency In USD
| Previous Close | 3.71 |
| Open | 3.75 |
| Day High | 3.89 |
| Day Low | 3.63 |
| 52-Week High | 4.13 |
| 52-Week Low | 0.69 |
| Volume | 2.95M |
| Average Volume | 6.46M |
| Market Cap | 752.59M |
| PE | -7.06 |
| EPS | -0.54 |
| Moving Average 50 Days | 3.37 |
| Moving Average 200 Days | 2.05 |
| Change | 0.1 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $188.06 as of January 06, 2026 at a share price of $3.81. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $131.74 as of January 06, 2026 at a share price of $3.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company’s presentation and participatio
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
GlobeNewswire Inc.
Dec 19, 2025 1:00 PM GMT
– Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed t
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
GlobeNewswire Inc.
Nov 21, 2025 1:00 PM GMT
– Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR)